VITURA HEALTH LIMITED (VIT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VIT - VITURA HEALTH LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: 0.48
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.38

09 Jun
2023

0.000

OPEN

$0.39

0.000

HIGH

$0.39

116,365

LOW

$0.38

TARGET
$0.90 136.8% upside
FNARENA'S MARKET CONSENSUS FORECASTS
VIT: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx 1.3 2.9 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A 0.0% xxx
PE Ratio xxx N/A 13.1 xxx
Dividend Yield xxx N/A 2.6% xxx
Div Pay Ratio(%) xxx 80.0% 34.5% xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20182019202020212022
EPS Basic xxxxxxxxxxxx1.3
DPS All xxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxx67.0 M
Book Value Per Share xxxxxxxxxxxx4.7
Net Operating Cash Flow xxxxxxxxxxxx13.5 M
Net Profit Margin xxxxxxxxxxxx9.03 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20182019202020212022
Return on Capital Employed xxxxxxxxxxxx34.17 %
Return on Invested Capital xxxxxxxxxxxx30.08 %
Return on Assets xxxxxxxxxxxx21.78 %
Return on Equity xxxxxxxxxxxx34.17 %
Return on Total Capital xxxxxxxxxxxx46.45 %
Free Cash Flow ex dividends xxxxxxxxxxxx13.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20182019202020212022
Short-Term Debt xxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxx5 M
Total Debt xxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxx5.27

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20182019202020212022
Capex xxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxx0.56 %
Cost of Goods Sold xxxxxxxxxxxx54 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx3 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/05/2023

1

Buy

$0.90

136.84%

Vitura Health, the market in leader in medicinal cannabis distribution, has entered a 50:50 joint venture with PharmAla Biotech called Cortexa, to take on the Australian research and therapeutic supply markets for MDMA and psilocybin. The end game would be to establish domestic manufacturing operations.

Cortexa gets to benefit from Vitura's pharmacy relationships and distribution networks, and will hold the exclusive licence for PharmAla's manufacturing and intellectual property for MDMA and Psilocybin.

Under the deal, Cortex pays $250,000 a year for three years to PharmAla for licence fees, and a 5% royalty on net profit. Each company is on the hook for a  break fee of $500,000 in the event of breach of contract. Vitura will loan $2.2m for working capital at a rate of 5% plus per year, linked to the cash rate.

Meanwhile, the broker observes the Therapeutic Goods Administration has down-scheduled (reclassified to non-prescription) MDMA for post traumatic stress disorder and Psilocybin for treatment resistant depression from July 1, 2023, and considers this to be a strong accretive sign for Vitura.

Dividend forecasts fall.

Buy recommendation and 90c target price retained.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 1.00 cents and EPS of 2.90 cents.
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of 3.60 cents.
Access Stockbroker Research History >

VIT STOCK CHART

FNArena News on VIT

1
Australian Broker Call *Extra* Edition – Jun 07, 2023

Jun 07 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Feb 22, 2023

Feb 22 2023 - Daily Market Reports